Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Organogenesis (ORGO) had Income from Continuous Operations of $-96.27M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$43.76M |
|
$-99.34M |
|
$23.67M |
|
$20.08M |
|
$94.75M |
|
$-50.99M |
|
$0.11M |
|
$-50.88M |
|
$-50.88M |
|
$-96.27M |
|
|
Income from Continuous Operations |
$-96.27M |
$-96.27M |
|
$-96.27M |
|
$-50.99M |
|
$-44.41M |
|
128.67M |
|
128.67M |
|
$-0.77 |
|
$-0.77 |
|
| Balance Sheet Financials | |
$200.30M |
|
$101.53M |
|
$206.14M |
|
$406.45M |
|
$56.96M |
|
$10.82M |
|
$201.22M |
|
$258.18M |
|
$148.27M |
|
$116.49M |
|
$148.27M |
|
128.68M |
|
| Cash Flow Statement Financials | |
$-10.53M |
|
$-4.25M |
|
$-32.72M |
|
$94.33M |
|
$46.84M |
|
$-47.49M |
|
$6.69M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.52 |
|
-- |
|
-- |
|
0.07 |
|
0.08 |
|
45.90% |
|
-116.54% |
|
-116.54% |
|
-- |
|
-116.28% |
|
-227.03% |
|
$-14.77M |
|
-- |
|
-- |
|
-- |
|
0.11 |
|
0.81 |
|
0.43 |
|
207.62 |
|
-64.93% |
|
-82.64% |
|
-23.69% |
|
-60.51% |
|
$1.15 |
|
$-0.11 |
|
$-0.08 |
|